AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2014
Jan 2, 2014
32125_dirs_2014-01-02_67aba346-3e3e-4c88-94e9-c57e3b920298.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2013-12-30
Reporting Person: LONGENECKER JOHN P PHD (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-12-30 | Common Stock | M | 581 | $1.61 | Acquired | 581 | Direct |
| 2013-12-30 | Common Stock | M | 1345 | $1.61 | Acquired | 1926 | Direct |
| 2013-12-30 | Common Stock | M | 574 | $1.61 | Acquired | 2500 | Direct |
| 2013-12-30 | Common Stock | S | 2500 | $55.55 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-12-30 | Stock Option (right to buy) | $1.61 | M | 581 | Disposed | 2020-09-02 | Common Stock (581) | Direct |
| 2013-12-30 | Stock Option (right to buy) | $1.61 | M | 1345 | Disposed | 2020-09-02 | Common Stock (1345) | Direct |
| 2013-12-30 | Stock Option (right to buy) | $1.61 | M | 574 | Disposed | 2020-09-02 | Common Stock (574) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.
F3: The option vested as to 50% of the options upon the first anniversary of the Issuer's initial public offering and as to the remaining 50% of the options upon the second anniversary of the Issuer's initial public offering. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.
F4: The option vested as to 75% of the options on September 2, 2010 and vested as to the remaining 25% of the options in successive equal monthly installments for the subsequent 12 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.